Application 212527
- Type
- NDA
- Sponsor
- CIPLA USA INC.
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE | DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE | TABLET, FOR SUSPENSION; ORAL | EQ 50MG BASE; 300MG; 25MG | No | No |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 70669 | ORIG | 2022-03-31 |